leadf
logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics quickly hits first research milestone under Mallinckrodt deal

he latest cash sum was handed over after Silence completed pre-clinical work on SLN500 programme

Silence Therapeutics PLC -

Silence Therapeutics PLC (LON:SLN) has hit the first milestone in a deal with a US drugs company in just two months, triggering a US$2mln research payment.

The UK specialist in RNA therapeutics has already received US$20mln upfront from Mallinckrodt Pharmaceuticals as part of a potential multi-million dollar collaboration unveiled in July.

WATCH: Silence Therapeutics hits first milestone in Mallinckrodt deal

The latest cash sum was handed over after Silence completed pre-clinical work on SLN500 programme, which is developing drugs to inhibit or 'silence' the complement cascade.

This is a group of proteins that are involved in the immune system and that play a role in the development of inflammation.

The AIM-listed drug developer could receive up to US$10mln of research milestones and a further US$100mln in regulatory and clinical payments. Much further down the track, commercial payments could add up to US$503mln.

"Our partnership with Mallinckrodt has proved both exciting and productive and the triggering of this first research milestone highlights the rapid progress which has been achieved to date through the collaboration,” said chief executive, David Horn Solomon.

“We remain committed to progressing SLN500 into clinical development and we look forward to further milestones as we rapidly develop this and potentially other innovative assets targeting the complement pathway."

Quick facts: Silence Therapeutics PLC

Price: 463 GBX

AIM:SLN
Market: AIM
Market Cap: £383.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Silence Therapeutics 'in a hot space with few competitors'

Silence Therapeutics' (LON:SLN) executive chair Annalisa Jenkins sat down with Proactive's Andrew Scott to discuss her strategy for taking the drug developer forward and the 'exciting opportunities' in the RNAi space. On what attracted Jenkins to join Silence, she says: ''The opportunity...

on 12/6/18

2 min read